Clinical Trials

Building on clinical trial and laboratory research insights from the past decade, the ITN has focused and deliberate strategies to achieving tolerance in each disease area. The research supported by the ITN has unlocked new therapeutic approaches and discovered new biomarkers that promise to change the way physicians treat patients. Explore ITN clinical trials below by using a search term or by sorting the specific trial categories. If you have questions or want more information about ITN clinical trials, contact us.

Allergen ISS Conjugates in Allergic Rhinitis

Principal Investigator:

Peter Creticos | Johns Hopkins University | Baltimore, MD

This study will evaluate the effectiveness of a six-week course of a DNA-based vaccine for seasonal allergic rhinitis, also known as hayfever.

Category: 

Allergy & Asthma

|

Specific Category: 

Ragweed Allergy

|

Status: 

Completed

Multicenter Trial of Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol

Principal Investigator:

James Shapiro | University of Alberta | Edmonton, Alberta | Canada

This was a multicenter clinical trial of the Edmonton protocol for islet transplantation.

Category: 

Transplantation

|

Specific Category: 

Islet Transplantation

|

Status: 

Completed

A Phase I Study: Safety of RG2077 (CTLA4-IgG4m) in Patients With Relapsing-Remitting Multiple Sclerosis

Principal Investigator:

Samia Khoury | Brigham & Women's Hospital | Boston, MA

Multiple sclerosis (MS) is an autoimmune disorder. In this disease, the body's immune system attacks and destroys the cells that cover and protect nerves. This study will test the safety of a new drug called RG2077 that is designed to treat MS. The study will not determine whether RG2077 is effective in treating MS, only whether it is safe to use in patients with MS.

Category: 

Autoimmune Disease

|

Specific Category: 

Multiple Sclerosis

|

Status: 

Completed

Mixed Chimerism and Renal Allograft with Non-Myeloablative Conditioning in Patients with ESRD Due to Multiple Myeloma

Principal Investigator:

Megan Sykes | Massachusetts General Hospital | Boston, MA

The purpose of this study is to determine whether a combined bone marrow and kidney transplant will be effective in treating stage II or greater multiple myeloma and associated kidney failure. This study will determine whether transplant rejection and the need for immunosuppressive drugs are decreased with this combined transplant approach.

Category: 

Transplantation

|

Specific Category: 

Kidney Transplantation

|

Status: 

Completed

Mixed Chimerism I: Renal Allograft Tolerance Through Mixed Chimerism

Principal Investigator:

David H. Sachs | Massachusetts General Hospital | Boston, MA

A. Benedict Cosimi | Massachusetts General Hospital | Boston, MA

This study examines the safety and effectiveness of a combination kidney and bone marrow transplant from a relative with the same (or nearly the same) blood cell type as the transplant recipient. An investigational medication will be given prior to and after the transplant to help protect the transplanted kidney from attack by the body's immune system.

Category: 

Transplantation

|

Specific Category: 

Kidney Transplantation

|

Status: 

Completed

Treatment of Psoriatic Arthritis with hOKT3γ(Ala-Ala): Psoriatic Arthritis Research Trial (PART)

Principal Investigator:

Marcus Clark | University of Chicago | Chicago, IL

hOKT3gamma1 (Ala-Ala) is a man-made antibody that is commonly used to prevent organ rejection. The purpose of this study is to determine whether hOKT3gamma1 (Ala-Ala) is safe and effective in psoriatic arthritis patients who are unable to control their arthritis with methotrexate or azathioprine.

Category: 

Autoimmune Disease

|

Specific Category: 

Psoriatic Arthritis

|

Status: 

Completed

Autoantigen Vaccination in Human Type 1 Newly Diagnosed Diabetes Mellitus

Principal Investigator:

Tihamer Orban | Joslin Diabetes Center | Boston, MA

In addition to regulating blood sugar, insulin may have the ability to protect cells in the pancreas from attack by the immune system. This study will evaluate whether an insulin-based vaccine can protect cells from autoimmune destruction.

Category: 

Type 1 Diabetes

|

Specific Category: 

|

Status: 

Completed

Campath-1H/Tacrolimus/Sirolimus Withdrawal in Renal Transplantation

Principal Investigator:

Stuart Knechtle | University of Wisconsin | Madison, WI

The purpose of this study is to test the safety and effectiveness of using alemtuzumab in combination with two other drugs, sirolimus and tacrolimus, to prevent organ rejection after kidney transplantation. This study will also test whether this combination of medications will allow patients to eventually stop taking antirejection medications entirely.

Category: 

Transplantation

|

Specific Category: 

Kidney Transplantation

|

Status: 

Completed

Proleukin® and Rapamune® in Type 1 Diabetes Mellitus (IL2-RAPA)

Principal Investigator:

Carla Greenbaum | Benaroya Research Institute | Seattle, WA

This is a phase I trial in individuals who have been diagnosed with type 1 diabetes within the previous 3-48 months. The study is testing whether two immune system modifying drugs are safe when used in combination and if they have immune altering effects that indicate they can halt the progression of type 1 diabetes.

Category: 

Type 1 Diabetes

|

Specific Category: 

|

Status: 

Completed

Efficacy and Safety Evaluation of Allergen Immunotherapy Co-Administered with Omalizumab, an anti-IgE Monoclonal Antibody

Principal Investigator:

Thomas B. Casale | Creighton University School of Medicine | Omaha, NE

A series of allergy shots may reduce symptoms of seasonal ragweed allergies. This study will determine whether taking a drug called omalizumab (also known as Xolair) before getting the allergy shots is more effective than allergy shots alone or other treatments, such as prescription antihistamines.

Category: 

Allergy & Asthma

|

Specific Category: 

Ragweed Allergy

|

Status: 

Completed

No items found.